EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System

Chenoa Sankar, Stephen Evans, Johanna Catharina Meyer, Hannah May Gunter, Victoria Sekiti, Kerrigan McCarthy

Drug Safety · 2025

DOI: 10.1007/s40264-025-01547-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Safety, 2025. Verfasst von Chenoa Sankar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health Surveillance and Response, National Institute for Communicable Diseases, Johannesburg, South Africa. ChenoaS@nicd.ac.za. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Pretoria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Monitoring of adverse events following immunisation (AEFI) is recommended for post-licensure surveillance. We investigated whether the South African surveillance system could detect signals of disproportionate reporting and whether these signals aligned with globally identified AEFI and adverse events of special interest (AESI) post-coronavirus disease-2019 (COVID-19) vaccination. METHODS: This retrospective pharmacovigilance study undertook disproportionality analysis of the National Department of Health AEFI database from the start of the COVID-19 vaccine rollout on 17 May 2021 to 31 December 2022. We complemented this with AEFI reports for vaccines not on the routine Expanded Programme on Immunisation schedule, to address potential masking of signals due to the high reporting rate of COVID-19 vaccine AEFI. RESULTS: During the study period, 3846 AEFI were reported for 37,537,009 doses of COVID-19 vaccines (BNT162b2 and Ad26.COV2.S) administered. The overall reporting rate was 10.2 per 100,000 doses, 18.1/100,000 and 7.9/100,000 for Ad26.COV2.S and BNT162b2, respectively. Comparison with other countries suggests underreporting. Disproportionate reporting signals were obtained for three and seven AEFI following BNT162b2 and Ad26.COV2.S vaccines, respectively. An additional three AEFI signals from Ad26.COV2.S emerged in the augmented dataset, indicating masking. All Ad26.COV2.S signals, and one BNT162b2 signal, appear in the vaccines' product information. Among nine AESI evaluated, myocarditis/pericarditis presented as a signal of disproportionate reporting following BNT162b2 vaccination. CONCLUSIONS: This study is one of the first from a lower-middle-income country, using a spontaneous reporting system for signal detection post-COVID-19 vaccination. Signals aligned with those reported globally. The study highlights the need to further investigate underreporting, masking, and system attributes for system strengthening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsCOVID-19 VaccinesCOVID-19HumansSouth AfricaRetrospective StudiesPharmacovigilanceBNT162 VaccineAdultFemaleAdolescentMaleMiddle AgedChildYoung AdultChild, PreschoolInfant

Substanzen

COVID-19 VaccinesBNT162 Vaccine

Autor:innen und Institutionen

  • Division of Public Health Surveillance and Response, National Institute for Communicable Diseases, Johannesburg, South Africa. ChenoaS@nicd.ac.za.
  • Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. ChenoaS@nicd.ac.za.
  • London School of Hygiene and Tropical Medicine, London, UK.
  • Department of Public Health Pharmacy and Management, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
  • South African Vaccination and Immunisation Centre, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Förderung

  • University of Pretoria

Zitieren

APA

Sankar, C., Evans, S., Meyer, J. C., Gunter, H. M., Sekiti, V., & McCarthy, K. (2025). Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System. Drug Safety. https://doi.org/10.1007/s40264-025-01547-4

Vancouver

Sankar C, Evans S, Meyer JC, Gunter HM, Sekiti V, McCarthy K. Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System. Drug Safety. 2025. doi:10.1007/s40264-025-01547-4

BibTeX
@article{Sankar2025,
  author = {Sankar, Chenoa and Evans, Stephen and Meyer, Johanna Catharina and Gunter, Hannah May and Sekiti, Victoria and McCarthy, Kerrigan},
  title = {Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System},
  journal = {Drug Safety},
  year = {2025},
  doi = {10.1007/s40264-025-01547-4}
}
Kostenlos starten →